title: [National guidelines for the management of patients with chronic lymphocytic leukemia. Sociedad Espan˜ola de Hematologı´a y Hemoterapia and Grupo Espan˜ol de Leucemia Linfocı´tica Cro´ nica].
abstract: Chronic lymphocytic leukemia is the most common chronic lymphoproliferative disorder in Spain. The clinical management of this entity varies widely. Currently, in Spain, there are no national consensus guidelines, such as those published in other countries, to guide the diagnosis and treatment of this malignancy and the use of prognostic scores. This article reviews the current scientific literature and addresses issues on the diagnosis of chronic lymphocytic leukemia, the spread of the disease, the presence of comorbidities, the classification of prognostic scores, the common treatment regimens stratified by risk factors, and the management of complications associated with both the disease and its treatment, as well as the various controversies related to this entity. This document was drafted with the collaboration of national experts and aims to establish practical guidelines with their corresponding levels of evidence and grades of recommendation to guide the diagnosis, treatment and follow-up of patients with chronic lymphocytic leukemia.
authors.affiliation: Servicio de Hematología, Hospital Puerta de Hierro, Majadahonda, Madrid, España.
authors.forename: José A
authors.initials: JA
authors.lastname: García Marco
authors.forename: Pilar
authors.initials: P
authors.lastname: Giraldo Castellano
authors.forename: Javier
authors.initials: J
authors.lastname: López Jiménez
authors.forename: Eduardo
authors.initials: E
authors.lastname: Ríos Herranz
authors.forename: José Luis
authors.initials: JL
authors.lastname: Sastre Moral
authors.forename: M José
authors.initials: MJ
authors.lastname: Terol Casterá
authors.forename: Francesc
authors.initials: F
authors.lastname: Bosch Albareda
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001803:Blood Transfusion; D003131:Combined Modality Therapy; D015897:Comorbidity; D019468:Disease Management; D019317:Evidence-Based Medicine; D006402:Hematologic Diseases / Q000209:etiology / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016867:Immunocompromised Host; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery; D009894:Opportunistic Infections / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D011379:Prognosis; D012008:Recurrence; D012307:Risk Factors; D016879:Salvage Therapy; D014611:Vaccination
keywords: Bendamustina; Bendamustine; Chlorambucil; Chronic lymphocytic leukemia; Chronic lymphoproliferative disorder; Clorambucilo; Fludarabina; Fludarabine; Leucemia linfocítica crónica; Rituximab; Síndrome linfoproliferativo crónico